Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hoffman

Showing results (461-470 of 470) with videos related to

Pageof 47
Sort By:
You have reached the last page of results.This site can display upto 470 results.
Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvantSylvia Adams, David W O'Neill, Daisuke Nonaka, et al.
Breast Cancer Research and Treatment|June 8, 2011
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathwaysCatherine Ibarra-Drendall, Michelle M Troch, William T Barry, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsAndrew M Scott, Fook-Thean Lee, Niall Tebbutt, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 26, 2019
Recommendations towards standards for quantitative MRI (qMRI) and outstanding needsKathryn E Keenan, Joshua R Biller, Jana G Delfino, et al.
Science Translational Medicine|June 7, 2019
Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune toleranceElise M N Ferré, Timothy J Break, Peter D Burbelo, et al.
Science (New York, N.Y.)|September 16, 2021
Response to Comments on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections"Timothy J Break, Vasileios Oikonomou, Nicolas Dutzan, et al.
Science (New York, N.Y.)|January 15, 2021
Aberrant type 1 immunity drives susceptibility to mucosal fungal infectionsTimothy J Break, Vasileios Oikonomou, Nicolas Dutzan, et al.
Pageof 47

Showing results (461-470 of 470) with videos related to

Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 470 results.
Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvantSylvia Adams, David W O'Neill, Daisuke Nonaka, et al.
Breast Cancer Research and Treatment|June 8, 2011
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathwaysCatherine Ibarra-Drendall, Michelle M Troch, William T Barry, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsAndrew M Scott, Fook-Thean Lee, Niall Tebbutt, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humansIan D Davis, Weisan Chen, Heather Jackson, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 26, 2019
Recommendations towards standards for quantitative MRI (qMRI) and outstanding needsKathryn E Keenan, Joshua R Biller, Jana G Delfino, et al.
Science Translational Medicine|June 7, 2019
Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune toleranceElise M N Ferré, Timothy J Break, Peter D Burbelo, et al.
Science (New York, N.Y.)|September 16, 2021
Response to Comments on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections"Timothy J Break, Vasileios Oikonomou, Nicolas Dutzan, et al.
Science (New York, N.Y.)|January 15, 2021
Aberrant type 1 immunity drives susceptibility to mucosal fungal infectionsTimothy J Break, Vasileios Oikonomou, Nicolas Dutzan, et al.
Pageof 47